Publications by authors named "Cheng-Dao Tsai"
Article Synopsis
- Type 2 diabetes is a growing global health issue, with projections suggesting over half a billion cases by 2030, increasing risks for heart-related complications.
- Two new types of diabetes medications have shown promise in reducing cardiovascular issues through various clinical trials.
- The Taiwan Society of Cardiology has created a consensus pathway to better integrate these therapies into patient care, supporting existing clinical guidelines.
Article Synopsis
- * Clinical trials initiated after a 2008 FDA mandate on cardiovascular safety for new diabetes medications have shown that some new agents can reduce cardiovascular (CV) risks and improve outcomes compared to older treatments.
- * The Taiwan Society of Cardiology and the Diabetes Association of Republic of China have developed updated treatment guidelines aimed at managing type 2 diabetes in patients with various cardiovascular conditions and risk factors.
Fixed-dose combinations (FDCs) are one of the options for improving blood pressure (BP) goal attainment. We enrolled 141 patients and evaluated the efficacy and safety between a fixed dose of olmesartan/amlodipine (OA) and a double dose of amlodipine (DA) for treating mild to moderate hypertension after amlodipine monotherapy failure. After at least 2 weeks of monotherapy failure, the patients were randomized to receive either OA or DA for 8 weeks.
View Article and Find Full Text PDF